Electron activated dissociation (EAD) and the Zeno trap provide high sensitivity and certainty in mass spectrometry results. 

Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.

The Scientist Social Club sat down with the author.

Immunologists and parasitologists are working to revive the idea that helminths, and more specifically the molecules they secrete, could help treat allergies and autoimmune disease.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

RNA editing platforms leverage the natural activity of ADAR enzymes to make key changes to messenger RNAs before they are translated into proteins.

Targeted, genome-wide CRISPR editing in yeast improves protein yield.

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

Now showing clinical progress against liver diseases, the gene-silencing technique begins to fulfill some of its promises.

A government lab finds a novel virus present in cell lines used for therapeutic production that were thought to be virus-free.

Clostridium difficile is evolving more robust toxicity, repeatedly attacking its victims, and driving the search for alternative therapies to fight the infection.